Nalaganje...
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
Epidermal growth factor receptor (EGFR) mutations (EGFRm(+)) occur in 10–35% of non-small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs are standard treatments for NSCLC patients harboring EGFR exon 19 deletions or exon 21 L858R point muta...
Shranjeno v:
| izdano v: | Oncotarget |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Impact Journals LLC
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5610029/ https://ncbi.nlm.nih.gov/pubmed/28969097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19925 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|